These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17434108)

  • 1. Intensity modulated high-dose-rate brachytherapy boost complementary to external beam radiation for intermediate- and high-risk localized prostate cancer patients--how we do it in Lübeck/Germany.
    Kovács G; Melchert C; Sommerauer M; Walden O
    Brachytherapy; 2007; 6(2):142-8. PubMed ID: 17434108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
    Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
    Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
    Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenge of dose escalation in locally advanced unfavourable prostate cancer using HDR brachytherapy.
    Al-Salihi O; Mitra A; Payne H
    Prostate Cancer Prostatic Dis; 2006; 9(4):370-3. PubMed ID: 16832383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
    Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
    Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K; Blacksburg S; Stone N; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients.
    Prada PJ; Fernández J; Martinez AA; de la Rúa A; Gonzalez JM; Fernandez JM; Juan G
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):95-102. PubMed ID: 17707267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
    Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
    Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone.
    Wilder RB; Barme GA; Gilbert RF; Holevas RE; Kobashi LI; Reed RR; Solomon RS; Walter NL; Chittenden L; Mesa AV; Agustin JK; Lizarde J; Macedo JC; Ravera J; Tokita KM
    Brachytherapy; 2010; 9(4):341-8. PubMed ID: 19853534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on prostate brachytherapy: long-term outcomes and treatment-related morbidity.
    Kao J; Cesaretti JA; Stone NN; Stock RG
    Curr Urol Rep; 2011 Jun; 12(3):237-42. PubMed ID: 21399887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EUS-guided fiducial placement before targeted radiation therapy for prostate cancer.
    Yang J; Abdel-Wahab M; Ribeiro A
    Gastrointest Endosc; 2009 Sep; 70(3):579-83. PubMed ID: 19560140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
    Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.